MA-VERISTAT
Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.
Veristat , a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.
“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”
Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:
- The ability to develop your therapeutic with accelerated approval pathways and/or special designations
- A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
- Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
- Expertise in logistics and handling of live cellular material
- Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
- Long-term follow-up strategies to meet global regulatory requirements
“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”
About Veristat:
Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005181/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Joins the Decentriq Network to Enable Secure Data Collaboration for Marketers and Agencies Across Europe16.9.2025 12:00:00 CEST | Press release
NIQ, a leading consumer intelligence company, is entering a strategic relationship with Decentriq to enable data collaboration for media use cases across Europe. Through the relationship, NIQ’s high quality consumer insights, including digital purchase data, will be available in Decentriq’s privacy-preserving clean rooms for the first time, enabling advertisers and agencies to utilize the data for audience profiling and closed loop measurement. Expanding beyond shopper insights NIQ is expanding its services to the data and media ecosystem through privacy-persevering clean rooms, opening up new opportunities for marketing and advertising agencies to enrich their first-party data insights, inform audience strategies, and measure sales outcomes. As Pierre Cholet, Chief Customer Officer at Decentriq, explains, “NIQ has long been a trusted name in understanding consumer purchasing behavior. Now, by integrating their data into Decentriq’s clean room, advertisers and agencies can leverage thi
Businesses Scale Transformation to Meet Regulatory, Technology and Customer Challenges, Finds Arthur D. Little Global Research16.9.2025 11:45:00 CEST | Press release
Transformation is now a way of life for global companies, with two-thirds (65%) undergoing wide-reaching or expanding organization-wide transformation initiatives. This is driven by regulatory change (including tariffs), technological disruption, and shifting customer needs, all of which are rated at 4.1/5 in importance. Confidence levels are high, with 95% expecting initiatives to deliver success, according to the inaugural Arthur D. Little (ADL) Global Transformation Study. Time frames vary significantly between regions. 71% have a four-to-six-year window for transformation, with 32% focused on five years. However, average timelines range from 3.2 years in North America to 4.9 years in the Middle East and 5.5 years in Asia-Pacific. There are also significant differences between who leads transformation efforts globally. While a third (32%) of companies have a Chief Transformation Officer (CTrO), adoption varies considerably by region. 53% of European companies have a CTrO, compared w
Reply Achieves the AWS Advertising and Marketing Technology Competency Thanks to the Contribution of the Data Reply and Storm Reply Teams16.9.2025 10:40:00 CEST | Press release
Reply [EXM, STAR: REY] has achieved the AWS Advertising and Marketing Technology Competency, the official recognition from Amazon Web Services certifying advanced technical and project expertise in the design and delivery of advertising and marketing solutions on AWS. This milestone was made possible thanks to the joint contribution of Storm Reply and Data Reply, both part of the Reply Group, with solid expertise in implementing cloud-native and data-driven solutions on the AWS platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916374888/en/ With this certification, Reply’s companies specialized in AWS services further consolidate their role as trusted technology partners for organizations looking to evolve their marketing and communication strategies through the advanced use of AWS cloud and AI technologies. The AWS Advertising and Marketing Technology Competency validates the ability of AWS Partners to deliver hig
PayPay Is Now Accepted in South Korea via Ant International’s Alipay+16.9.2025 10:26:00 CEST | Press release
Connecting 70 million PayPay users to over 2 million South Korean merchants A milestone in PayPay’s overseas expansion Starting from late September 2025, Japan's leading cashless payment service PayPay will be accepted at over 2 million merchants across South Korea through Alipay+, a global wallet gateway service operated by Ant International. This will allow its 70 million registered users to make seamless payments during their visit, wherever the Alipay+ logo is displayed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915612411/en/ Starting from late September 2025, Japanese travellers will be able to use PayPay to make payments in South Korea at stores displaying the Alipay+ logo. PayPay will show users the payment amount in Korean won and its yen equivalent in real time. This marks a new chapter in PayPay’s overseas expansion. From K-beauty stores and convenience chains to local eateries and cultural hotspots, from m
Talent shortages and AI pressures drive shifting dynamics in global technology leadership, According to Expereo16.9.2025 10:00:00 CEST | Press release
Skills gaps in networking, cybersecurity, and AI are delaying growth and forcing businesses to rethink leadership, training, and investment strategies Global businesses are facing mounting challenges in their growth ambitions due to persistent skills shortages in critical technology areas. As AI becomes more deeply embedded in business strategy, organisations are struggling to find or retain talent in key domains such as networking (39%), cybersecurity (40%), and Data/AI/automation (33%). The findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” The report reveals that 39% of organisations are struggling to find or retain networking talent, while 33% report similar challenges in data, AI, and automation - figures that remain consistent with 2024 findings. These shortages are not only slowing down AI adoption but also reshaping leadership dynamics and workforce strategies across enterpris
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom